<DOC>
	<DOCNO>NCT02238119</DOCNO>
	<brief_summary>Study evaluate lung function response free once-daily combination tiotropium + formoterol compare formoterol BID tiotropium QD</brief_summary>
	<brief_title>Efficacy Safety Free Combination Tiotropium + Formoterol Compared Formoterol Tiotropium Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . All patient sign inform consent consistent International Conference Harmonization Good Clinical Practice ( ICHGCP ) guideline prior participation trial , include medication washout restriction 2 . All patient diagnosis chronic obstructive pulmonary disease meet follow spirometric criterion : Patients relatively stable moderate severe airway obstruction FEV1 ≤ 60 % predict normal FEV1 ≤ 70 % FVC ( Visits 1 2 ) 3 . Male female patient 40 year age old 4 . Patients current exsmokers smoke history 10 packyears ( Patients never smoke cigarette exclude ) 5 . Patients able perform technically acceptable pulmonary function test able maintain record ( Patient Daily Diary Record ) study period require protocol 6 . Patients able inhale medication competent manner HandiHaler® device , Blue Inhaler device meter dose inhaler ( MDI ) 1 . Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study 2 . Patients clinically relevant abnormal baseline haematology , blood chemistry , urinalysis abnormality define disease list exclusion criterion 3 . All patient serum glutamate oxaloacetate transaminase ( SGOT ) &gt; 80 IU/L , serum glutamate pyruvate transaminase ( SGPT ) &gt; 80 IU/L , bilirubin &gt; 17 μmol/L creatinine &gt; 110 μmol/L ( male ) / 95 μmol/L ( female ) exclude regardless clinical condition 4 . Patients recent history ( i.e. , six month less ) myocardial infarction 5 . Patients cardiac arrhythmia require drug therapy hospitalise heart failure within past three year 6 . Patients history cancer within last five year . Patients treat basal cell carcinoma allow 7 . Patients know symptomatic prostatic hypertrophy bladder neck obstruction . Patients prostatic hypertrophy control medication allow 8 . Patients know narrowangle glaucoma 9 . Patients history asthma , allergic rhinitis total blood eosinophil count ≥600 mm3 10 . Patients history lifethreatening pulmonary obstruction , history cystic fibrosis clinically evident bronchiectasis 11 . Patients know active tuberculosis 12 . Patients history and/or active significant alcohol drug abuse . See exclusion criterion No . 1 . 13 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No . 1 14 . Patients complete pulmonary rehabilitation program six week prior Screening Visit ( Visit 1 ) 15 . Patients regularly use daytime oxygen therapy 16 . Patients take investigational drug within one month six half life ( whichever great ) prior Screening Visit ( Visit 1 ) 17 . Patients treat betablocker medication . Note : cardioselective beta blocker eye medication ( e.g . Betoptic® ) treatment nonnarrow angle glaucoma allow 18 . Patients treat oral betaadrenergics 19 . Patients treat cromolyn sodium nedocromil sodium 20 . Patients treated antihistamine ( H1 receptor antagonist ) , antileukotrienes leukotriene receptor antagonist asthma exclude allergic condition . See exclusion criterion No . 9 21 . Patients use oral corticosteroid medication unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day 22 . Patients know hypersensitivity anticholinergic drug , betaadrenergics , lactose component inhalation capsule delivery system 23 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception previous 3 month ( i.e . oral contraceptive , intrauterine device , diaphragm subdermal implant e.g. , Norplant® ) 24 . Patients previous participation ( receipt randomise treatment ) study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>